SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending as rival Hims & Hers has halted its compounded weight-loss pill following legal action from NVO and increased FDA scrutiny on such alternatives, reinforcing NVO's market leadership. The community is actively discussing the implications of this development alongside Novo's promising oral Wegovy launch momentum and ongoing share buyback program.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid renewed uncertainty surrounding global trade policy, driven by recent tariff decisions that have sparked market volatility. The community is sharply divided, with bears anticipating a major downturn following weekend declines, while bulls expect a typical 'V-shape' recovery, particularly ahead of key tech earnings this week.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community eagerly discusses the recent FDA approval of Bysanti for bipolar I disorder and schizophrenia, with many anticipating a significant valuation re-rating and potential for a short squeeze, especially given the drug's patent protection until 2044 and the broader 'mega blockbuster' potential of its pipeline.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's recent CagriSema trial results fuel intense community speculation that VKTX's 'best-in-class' VK2735 obesity drug is now an even more attractive buyout or partnership target for major pharmaceutical companies like AbbVie, given its strong efficacy and tolerability in the rapidly expanding weight loss market.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to its succession of record-breaking battery swaps, including hitting 1 million weekly swaps during the Chinese New Year holiday, which bulls highlight as proof of its BaaS ecosystem's strength and a precursor to anticipated profitability. However, the community remains divided, with skeptics dismissing holiday-inflated numbers and alleging continued stock manipulation, while broader discussions also focus on the potential impact of recent tariff rulings.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending as investors eagerly anticipate its upcoming earnings report, driving significant community speculation around a potential buyout and a short squeeze due to high short interest. Discussions are also focused on recent partnership announcements and institutional buying, with many comparing its current valuation to peers in the insurtech sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending amid reports of its aggressive AI chip expansion to rival Nvidia and the launch of its advanced Gemini 3.1 Pro AI model. The community is actively discussing the company's substantial CapEx and recent bond sale, debating whether these signal a visionary long-term investment in AI infrastructure or raise immediate valuation concerns.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending as investors await its earnings report and upcoming presentations of positive Navenibart trial data, a recently acquired long-acting HAE prophylactic. This is fueling community debate between optimism driven by institutional interest and persistent concerns over significant short positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acadia Healthcare to Participate in March Investor Conferences

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in three investor conferences in March. On Monday, March 2, 2026, the Company will participate in the...

Aberdeen Group plc Raises Stock Holdings in Acadia Healthcare Company, Inc. $ACHC

Aberdeen Group plc raised its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) by 24.0% during the 3rd quarter, according to its most recent disclosure with the Securities and...

Earnings Preview: Acadia Healthcare (ACHC) Q4 Earnings Expected to Decline

Acadia Healthcare (ACHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Healthcare (ACHC) to Release Earnings on Wednesday

Acadia Healthcare (NASDAQ:ACHC) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Public Sector Pension Investment Board Takes $8.92 Million Position in Acadia Healthcare Company, Inc. $ACHC

Public Sector Pension Investment Board purchased a new position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with...

Short Interest in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Increases By 20.0%

Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling...

LSV Asset Management Purchases New Stake in Acadia Healthcare Company, Inc. $ACHC

LSV Asset Management acquired a new position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) in the third quarter, according to the company in its most recent disclosure with the...

Principal Financial Group Inc. Grows Holdings in Acadia Healthcare Company, Inc. $ACHC

Principal Financial Group Inc. grew its stake in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) by 112.1% in the third quarter, according to its most recent disclosure with the...

Acadia Healthcare (NASDAQ:ACHC) Trading 12.9% Higher - Still a Buy?

Acadia Healthcare (NASDAQ:ACHC) Shares Up 12.9% - Should You Buy...

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Acadia Healthcare Securities Litigation

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Acadia Healthcare Securities Litigation: UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE...

Acadia Healthcare Co., Inc. engages in the provision of behavioral healthcare services across the United States. The firm provides services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics. The company was founded in January 2005 and is headquartered in Franklin, TN.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.01	--	--	N/A
Q3 '25	$0.66	$0.72	9.15%	BEAT
Q2 '25	$0.69	$0.83	19.46%	BEAT
Q1 '25	$0.36	$0.40	12.06%	BEAT
Q4 '24	$0.71	$0.64	-10.44%	MISSED

ACHC
Acadia Healthcare Company Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ACHC News

ACHCAcadia Healthcare Company Inc